<DOC>
	<DOCNO>NCT02290977</DOCNO>
	<brief_summary>The presence portal vein tumor thrombosis ( PVTT ) patient hepatocellular carcinoma ( HCC ) one significant prognostic factor poor prognosis , without treatment , survival le 3 month . In HCC patient combine PVTT , Radiation therapy ( RT ) show 50 % local control 10 month survival duration . Despite standard treatment HCC combine PVTT sorafenib , Korean Liver Cancer Study Group ( KLCSG ) recommend RT alternative option patient . Investigators previously report retrospective study schedule interval Trans-catheter Arterial Chemo-embolization ( TACE ) follow RT HCC combine PVTT 60 % patient show objective response without significant elevation complication . However , prospective outcome TACE follow RT HCC scantly report . Based background , start prospective study evaluate clinical outcome adverse event RT TACE unresectable HCC patient combine PVTT .</brief_summary>
	<brief_title>Transarterial Chemoembolization ( TACE ) With Radiation Therapy ( RT ) Advanced Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<criteria>1 . Patients must diagnosis HCC least one criterion list ( korean liver cancer study group ( KLCSG ) guideline 2009 ) 1.1 Pathologically ( histologically cytologically ) proven diagnosis HCC 1.2 Liver nodule high risk group 1.2.1 If alpha fetoprotein ( AFP ) ≥200 ng/mL , ≥ 1 typical HCC enhance pattern dynamic contrast enhance CT MRI 1.2.2 If AFP &lt; 200 ng/mL , ≥2 typical HCC enhance pattern dynamic contrast enhance CT , MRI , angiography 1.3 ≥ 2 cm nodule liver cirrhosis ( LC ) , ≥ 1 typical HCC enhance pattern dynamic contrast enhance CT MRI 2 . Patients must diagnosis PVTT 2.1 Early arterial enhancement delay washout multiphasic CT MRI 3 . Eastern cooperative oncology group performance status 0 1 2 4 . Age ≥ 20 70 less 5 . Unsuitable resection transplant radiofrequency ablation ( RFA ) 6 . Unsuitable refractory TACE drug elute bead ( DEB ) 7 . Agreement studyspecific inform consent 8 . Assessment radiation oncologist medical oncologist hepatologist within 28 day prior study entry ? 9 . ChildPugh score AB within 7 day prior study entry 10 . Normal liver ( Liver minus gross tumor volume ) ≥ 700 cc 11 . Blood work requirement Absolute neutrophil count ( ANC ) ≥ 1,500 /mm3 , Platelet ≥ 70,000/mm3 , Hgb ≥ 8 g/dl Liver function test ( LFT ) : Total bilirubin &lt; 3.0 mg/dL , International normalize ratio ( INR ) &lt; 1.7 , Albumin ≥ 2.8g/dL , Aspartate aminotransferase ( AST ) /Alanine aminotransferase ( ALT ) &lt; 6 X normal Serum creatinine &lt; 1.5 X normal , creatinine clearance ≥ 60 mL/min 12 . Male , consent contraception least 6 month 13 . Childbearing potential woman , consent contraception least 6 month 14 . Life expectancy 12 week 15 . Stable breathe 5 minute 1 . Complete obstruction main portal vein 2 . Pregnant and/or breastfeed woman 3 . Previous upper abdominal RT history 4 . Uncontrolled active comorbidity 5 . Another primary cancer history within 2 year 6 . Uncontrolled ascites hepatic encephalopathy 7 . Connective tissue disease know radiation hypersensitivity 8 . Uncontrolled moderate severe gastroduodenal ulcer esophagogastric varix</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>RT , TACE</keyword>
</DOC>